Eli Lilly welcomes the European Commission's (EC) commitment to strengthening CVD prevention through the Recommendation on CV health checks. CVD remains the leading cause of death in Europe. Tackling this burden requires an integrated approach, recognising CVD, diabetes, and obesity as interconnected conditions with common pathophysiological mechanisms.
ELC
Eli Lilly & Company
Company · United States · EU Transparency Register 04657143399-39
1
position filed
in the 326 files tracked
1
legislative file
of 326 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #652 by legislative files engaged — a count of participation, not a measure of influence.
1.9
declared lobbying FTE
self-declared
€900K+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2010
in the register since
Declares membership of
- Eli Lilly and Company is a member of the following associations and bodies: European Federation of Pharmaceutical Ind…
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Eli Lilly and Company (Lilly)
- Head office
- Indianapolis, United states
- EU office
- Brusselles / Brussel
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Eli in PolicySpeak: request access →
Work at Eli Lilly & Company? so we know who speaks for it.
Their record over time
Eli Lilly & Company filed 1 position on 19 May 2026, across 1 of the 326 legislative files tracked here, attaching a full position paper 1 time.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from Eli Lilly & Company’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.